Our Tokyo attorneys recognize how aggressive enforcement of U.S. laws affects clients in Japan and throughout Asia. As the U.S. Department of Justice and the Securities and Exchange Commission escalate the enforcement of the U.S.’s Foreign Corrupt Practices Act, antitrust laws, price-fixing and insider trading laws, Ropes & Gray’s Tokyo office is prepared to advise clients facing such governmental scrutiny. Our attorneys also are deeply experienced in handling the compliance and enforcement risks faced by Life Sciences companies operating in the United States, including those relating to good manufacturing practices, off-label marketing, drug pricing, and reimbursement concerns. Our experience can help clients avoid, resolve or mitigate any fallout with sound advice in a number of areas including: compliance programs, appropriate responses to threats, internal investigations, enforcement actions and the criminal process.
Recent matters include acting for:
- A major Japanese pharmaceutical company in defending against alleged drug-pricing violations.
- Certain Japanese executives in connection with a criminal price-fixing investigation by the U.S. Department of Justice.
- Certain Japanese companies in connection with a criminal investigation by the U.S. Department of Justice into price-fixing in international transportation markets.
- A major Japanese consumer product company, investigating and coordinating the response into data security and privacy breaches.
- Daewoo International Corporation, securing dismissal of price-fixing claims brought against our client alleging an international conspiracy to fix price charges for CRTs and CRT products.
- A major multi-national medical device manufacturer with operations in 70 countries by developing an FCPA compliance program.
- Global Knowledge Network, prevailing in a motion to dismiss all antitrust claims brought against our client, Global Knowledge Network, a worldwide leader in IT and business training, in an action alleging illegal tying.
- Sandata Technologies in defending antitrust counterclaims brought by an infringer in a patent-antitrust litigation.
- A multi-national corporation headquartered in France with more than 25,000 employees, developing a detailed FCPA risk assessment and compliance program and related anti-corruption training program.
- Pfizer in reaching a global settlement with the federal and state governments. Ropes & Gray led a multi-firm team working with Pfizer’s legal team in conducting an extensive internal investigation of the civil and criminal allegations and to resolve the various probes and lawsuits, and served as Pfizer’s lead outside counsel in negotiating the settlement agreement.
- A U.S. private equity firm active in Asia, developing a gifts and entertainment policy and a compliance program.
- Merck & Co., Inc., Schering Plough Corporation and the joint venture Merck-Schering Plough Pharmaceuticals regarding their joint venture anti-cholesterol drug Vytorin, after a widely publicized investigation by 36 state attorneys general in the United States.